FeesSafety
Pluang+

Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Company Fundamentals
23 Nov 2026, 05:30 WIB
The Motley Fool Team
View Source
Bullish
Alamar Biosciences raises 2026 revenue forecast to $121-$123M, driven by biopharma demand and clinical diagnostics expansion.

Alamar Biosciences increased its full-year 2026 revenue guidance to $121-$123 million, fueled by strong demand for consumables from biopharmaceutical clients who now represent 49% of Q3 revenue. The company’s NULISA platform was selected by the U.K. Biobank to profile 80,000 samples for neurodegenerative markers, validating its large-scale protein detection capabilities. Looking ahead, Alamar plans to submit its ARGO HT/DX clinical instrument for FDA approval by late 2027, aiming to expand into clinical diagnostics and population-scale screening beyond research. Management expects to grow its installed instrument base and launch new multiplex disease panels in 2027, supporting long-term recurring revenue growth.

Alamar Biosciences is the subject of this update, with Pluang providing Health-sector market data as context. As of Nov 23, 2026 06:02 WIB, among 150 priced Health-sector US stocks tradable on Pluang, 31 rose and 117 fell. Notable movers include NUWE at USD 3.41 with a -10.50% change, CGC at USD 0.43 with a -9.97% change, and RXRX at USD 2.45 with a -9.93% change. The most notable figure is the 117 stocks that declined today.

More News

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology posts record $69.5M Q3 revenue, targets $200M in 2026 amid AI infrastructure growth

Gorilla Technology reported a record $69.5 million in revenue for Q3 2026, driven by expanding AI infrastructure projects and hardware deliveries. The company reduced unbilled contract assets by over 50%, improving liquidity as it shifts focus from s...

Company Fundamentals
Bullish
26 minutes ago
Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway holds steady on Apple shares despite 29% price rise and high valuation in 2026.

Berkshire Hathaway has not sold any Apple shares in 2026, even as Apple's stock price rose 29% and its price-to-earnings ratio neared 40, indicating less concern about valuation. This decision reflects confidence in Apple's strong business fundamenta...

Market News
Bullish
30 minutes ago
US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

US invests $1.6B to build domestic rare-earth supply chain with USA Rare Earth leading Texas mine development.

The U.S. government is investing $1.6 billion to develop a domestic rare-earth supply chain, aiming to reduce reliance on China. USA Rare Earth is a key player, using the funds to build out mining and processing capabilities, including developing the...

Market News
Bullish
35 minutes ago
CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell raises 2026 revenue forecast to $115-$117M, boosts hospital accounts and gross margin to 90%.

CeriBell updated its full-year 2026 revenue guidance to $115 million to $117 million, driven by increased usage per hospital account and expansion by 35 new hospital accounts. The company improved its gross margin to 90% from 88% last year, supported...

Company Fundamentals
Bullish
35 minutes ago
Cryptocurrency markets stabilize after $1.8B forced sell-off, Bitcoin recovers above $60K.

Cryptocurrency markets stabilize after $1.8B forced sell-off, Bitcoin recovers above $60K.

Cryptocurrency markets showed signs of stabilization on November 22 after a severe sell-off caused about $1.8 billion in forced liquidations. Bitcoin rose 1.15% to $60,785, and Ethereum gained 2.23% to $1,719, while Solana slightly declined. The sell...

Neutral
45 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App